Surgical Resection Improves Survival in BCLC Stage C Hepatocellular Carcinoma
the Cancer Therapy Advisor take:
Surgical resection provides significantly better long-term survival compared to transarterial chemoembolization (TACE) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC), according to a study published in the Journal of Surgical Oncology.
Taiwanese researchers led by Po-Hong Lui, MD, of the Taipei Veterans General Hospital examined patients being treated for their HCC, 264 with surgical resection and 389 with TACE. Among these patients, 163 matched pairs were identified from each arm by propensity score analysis in order to compare long-term survival.
They found that the group that underwent surgical resection had better liver function reserve than the TACE group, and demonstrated better long-term survival. After matched propensity modeling, baseline characteristics were similar between the two groups.
In addition, with Cox proportional modeling, patients who underwent TACE had an increased risk of mortality compared to those who underwent surgical resection.
“Multidisciplinary approaches for these patients and further amendments to the BCLC classification scheme are required,” the authors concluded.
Surgical resection provides better survival compared to transarterial chemoembolization in hepatocellular carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed